CRIS Current Research Information System

DI FEDERICO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.510
NA - Nord America 2.711
EU - Europa 1.838
SA - Sud America 226
AF - Africa 203
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.494
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.629
VN - Vietnam 1.177
CN - Cina 1.110
SG - Singapore 1.072
IT - Italia 798
HK - Hong Kong 338
NL - Olanda 177
IN - India 174
BD - Bangladesh 171
DE - Germania 170
BR - Brasile 164
KR - Corea 163
SE - Svezia 120
GB - Regno Unito 98
FR - Francia 97
FI - Finlandia 91
JP - Giappone 65
IE - Irlanda 63
CH - Svizzera 62
CI - Costa d'Avorio 62
CA - Canada 49
RU - Federazione Russa 39
PH - Filippine 37
AR - Argentina 35
TG - Togo 35
TH - Thailandia 35
SC - Seychelles 31
ID - Indonesia 30
JO - Giordania 27
AT - Austria 26
NG - Nigeria 26
PL - Polonia 23
MX - Messico 21
ZA - Sudafrica 21
IQ - Iraq 19
TR - Turchia 17
ES - Italia 14
PK - Pakistan 14
TW - Taiwan 13
BG - Bulgaria 12
BE - Belgio 9
LT - Lituania 8
UA - Ucraina 8
CL - Cile 6
EC - Ecuador 6
UZ - Uzbekistan 6
DZ - Algeria 5
EG - Egitto 5
KE - Kenya 5
MY - Malesia 5
OM - Oman 5
SA - Arabia Saudita 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
GR - Grecia 4
MA - Marocco 4
PY - Paraguay 4
AL - Albania 3
AZ - Azerbaigian 3
CO - Colombia 3
IL - Israele 3
KZ - Kazakistan 3
NI - Nicaragua 3
NP - Nepal 3
PT - Portogallo 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
CR - Costa Rica 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NZ - Nuova Zelanda 2
PE - Perù 2
SN - Senegal 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GM - Gambi 1
GT - Guatemala 1
HN - Honduras 1
IS - Islanda 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
ML - Mali 1
MM - Myanmar 1
MT - Malta 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
Totale 9.492
Salva come PNG Salva come JPEG
Città #
Singapore 765
Ashburn 408
Hefei 339
Hong Kong 316
Ho Chi Minh City 294
Hanoi 266
San Jose 249
Dallas 180
Santa Clara 153
Seoul 144
Bologna 139
Beijing 137
Chandler 116
Boardman 111
New York 110
Council Bluffs 82
Los Angeles 74
Milan 68
Abidjan 62
Dublin 62
Fairfield 61
Helsinki 61
Dong Ket 54
Buffalo 49
Tokyo 44
Bern 43
Rome 43
Lauterbourg 41
São Paulo 41
Seattle 39
Haiphong 38
Houston 37
Princeton 37
Southend 36
Lomé 35
Hyderabad 33
Munich 33
Bengaluru 31
Da Nang 30
Frankfurt am Main 30
Shanghai 30
Turin 30
Amman 25
Redondo Beach 24
Woodbridge 24
Cinquefrondi 22
Guangzhou 21
Hải Dương 21
Abeokuta 20
Biên Hòa 20
Wilmington 20
Falkenstein 19
Jakarta 17
Modena 17
Orem 17
Amsterdam 16
Messina 16
Tianjin 16
Toronto 16
Turku 16
Visakhapatnam 16
Can Tho 15
London 15
Montreal 15
Warsaw 15
Johannesburg 14
Stockholm 14
Cambridge 13
Lappeenranta 13
The Dalles 13
Tongling 13
Quận Bình Thạnh 12
San Diego 12
San Francisco 12
Atlanta 11
Moncalieri 11
Naples 11
Phoenix 11
Sofia 11
Vienna 11
Xi'an 11
Florence 10
Ha Long 10
Ninh Bình 10
Nuremberg 10
Poplar 10
Brooklyn 9
Bắc Giang 9
Mumbai 9
Quận Một 9
Washington 9
Zhengzhou 9
Bangkok 8
Boydton 8
Bắc Ninh 8
Chicago 8
Denver 8
Rimini 8
Thái Nguyên 8
Berlin 7
Totale 5.734
Salva come PNG Salva come JPEG
Nome #
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 275
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 272
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 267
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 234
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 229
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 216
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 206
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 204
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 197
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 185
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 184
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 181
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 180
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 177
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 177
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 176
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 169
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 164
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 164
Hacking pancreatic cancer: Present and future of personalized medicine 162
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 160
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 157
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond 156
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 154
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? 147
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 147
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 146
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 142
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 141
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 138
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 135
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 134
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (Hcc) with orbital metastases: A case report 132
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients 131
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 125
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 121
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 118
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma 118
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 115
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 115
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 113
Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review 110
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 109
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 109
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 109
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 104
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 103
Nivolumab: an investigational agent for the treatment of biliary tract cancer 102
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 98
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review 91
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies 87
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 87
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 86
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 86
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 86
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 84
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 82
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 77
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation 73
Efficacy and Safety of TROP-2-Targeting Antibody–Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data 72
IMpower 132: Is the Second Exception to the Rule No Longer an Exception? 72
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 71
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 70
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 67
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 62
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 62
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 60
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 59
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? 59
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 57
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% 53
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities 52
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC 50
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects 50
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma 39
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 39
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 36
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer 35
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 29
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis 27
Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations 24
Totale 9.692
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.282
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.282
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202170 0 0 0 0 0 0 0 0 0 0 0 70
2021/2022355 15 1 4 17 16 8 4 49 50 25 119 47
2022/2023734 38 77 35 42 102 57 29 51 141 40 50 72
2023/2024359 45 33 19 25 21 65 13 41 13 33 38 13
2024/20252.078 89 145 176 119 216 102 216 93 46 216 211 449
2025/20265.918 673 620 499 441 372 252 534 189 1.058 502 464 314
Totale 9.692